Acylin Therapeutics, Inc. — Form D
Acylin Therapeutics, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2010-12-01. The offering totals $4.4M, of which $2.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2010-12-01
- Form: D
- Accession: 0001506358-10-000001
- Industry: Biotechnology
- Exemptions: 06
- Total offering: $4.4M
- Amount sold: $2.0M
- Remaining: $2.4M
- Investors: 7
- Date of first sale: 2010-11-18
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-151206
Issuer
- Name: Acylin Therapeutics, Inc.
- CIK: 0001506358
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2009
- Address: 1616 EASTLAKE AVE, SUITE 203, SEATTLE, WA, 98102
- Phone: 2069577300
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Steven Gillis | Director | South San Francisco, CA |
| Chad Waite | Director | SEATTLE, WA |
| THONG LE | Director | Seattle, WA |
| LINDSAY RAYLE | Executive Officer | New York, NY |
| Lee Babiss | Director | Cambridge, MA |
| Carl Weissman | Director | San Diego, CA |
| Carl Weissman | Executive Officer | San Diego, CA |
| Janis Naeve | Director | Gaithersburg, MD |
| Peter DiStefano | Director | Seattle, WA |
| Steven Gills | Director | Seattle, WA |
Other filings by this issuer (2)
More